Taiho Oncology Drug Patent Portfolio
Taiho Oncology owns 3 orange book drugs protected by 17 US patents Given below is the list of Taiho Oncology's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11963971 | Combination decitabine and cedazuridine solid oral dosage forms | 24 Feb, 2041 | Active |
| US12195496 | 2′-deoxy-2′,2′-difluorotetrahydrouridines with high purity and methods of making the same | 07 Oct, 2040 | Active |
| US11833151 | Pharmaceutical composition including sodium alkyl sulfate | 05 Nov, 2039 | Active |
| US10456399 | Method for treating cancer patients with severe renal impairment | 03 Feb, 2037 | Active |
| US10960004 | Method for treating cancer patients with severe renal impairment | 03 Feb, 2037 | Active |
| US10434103 | Crystal of 3,5-disubstituted benzene alkynyl compound | 31 Mar, 2036 | Active |
| US9943537 | Antitumor agent and antitumor effect enhancer | 05 Sep, 2034 | Active |
| US10457666 | Stable crystal form of tipiracil hydrochloride and crystallization method for the same | 17 Jun, 2034 | Active |
| US9527833 | Stable crystal form of tipiracil hydrochloride and crystallization method for the same | 17 Jun, 2034 | Active |
| US9108973 | 3,5-disubstituted alkynylbenzene compound and salt thereof | 23 Feb, 2033 | Active |
| US8268800 | Certain compounds, compositions and methods | 22 Aug, 2030 | Active |
| USRE46284 | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor | 22 Sep, 2029 | Active |
| US8618075 | Certain compounds, compositions and methods | 16 Oct, 2028 | Active |
| US9567363 | Certain compounds, compositions and methods | 16 Oct, 2028 | Active |
| US7799783 | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor | 16 Dec, 2026 | Active |
| US6479500 | Agents for alleviating side effects | 16 Mar, 2020 | Expired |
| US5744475 | Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same | 28 Mar, 2016 | Expired |
Latest Legal Activities on Taiho Oncology's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Taiho Oncology.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 12 Jun, 2024 | US9527833 |
| Letter from FDA or Dept of Agriculture re PTE application | 11 Jun, 2024 | US9108973 |
| Letter from FDA or Dept of Agriculture re PTE application | 11 Jun, 2024 | US10434103 |
|
Email Notification
Critical
| 20 Mar, 2024 | US11833151 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 20 Mar, 2024 | US11833151 |
| Notice of Final Determination- Ineligible | 18 Mar, 2024 | US10434103 |
| Notice of Final Determination- Ineligible | 18 Mar, 2024 | US9108973 |
| transaction for FDA Determination of Regulatory Review Period | 14 Mar, 2024 | US8618075 |
| transaction for FDA Determination of Regulatory Review Period | 14 Mar, 2024 | US9567363 |
| transaction for FDA Determination of Regulatory Review Period | 14 Mar, 2024 | US8268800 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 06 Mar, 2024 | US8268800 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US8268800 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US9567363 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US8618075 |
| Letter from FDA or Dept of Agriculture re PTE application | 24 Jan, 2024 | US9108973 |
Taiho Oncology Drug Patents' Oppositions Filed in EPO
Taiho Oncology drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jul 13, 2022, by Stada Arzneimittel Ag. This opposition was filed on patent number EP14814354A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP14814354A | Jul, 2022 | STADA Arzneimittel AG | Granted and Under Opposition |
Taiho Oncology's Family Patents
Taiho Oncology Drug List
Given below is the complete list of Taiho Oncology's drugs and the patents protecting them.
1. Inqovi
Inqovi is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11963971 | Combination decitabine and cedazuridine solid oral dosage forms |
24 Feb, 2041
(15 years from now)
| Active |
| US12195496 | 2′-deoxy-2′,2′-difluorotetrahydrouridines with high purity and methods of making the same |
07 Oct, 2040
(15 years from now)
| Active |
| US8268800 | Certain compounds, compositions and methods |
22 Aug, 2030
(5 years from now)
| Active |
| US8618075 | Certain compounds, compositions and methods |
16 Oct, 2028
(3 years from now)
| Active |
| US9567363 | Certain compounds, compositions and methods |
16 Oct, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Inqovi's drug page
2. Lonsurf
Lonsurf is protected by 9 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10456399 | Method for treating cancer patients with severe renal impairment |
03 Feb, 2037
(11 years from now)
| Active |
| US10960004 | Method for treating cancer patients with severe renal impairment |
03 Feb, 2037
(11 years from now)
| Active |
| US9943537 | Antitumor agent and antitumor effect enhancer |
05 Sep, 2034
(9 years from now)
| Active |
| US10457666 | Stable crystal form of tipiracil hydrochloride and crystallization method for the same |
17 Jun, 2034
(9 years from now)
| Active |
| US9527833 | Stable crystal form of tipiracil hydrochloride and crystallization method for the same |
17 Jun, 2034
(9 years from now)
| Active |
| USRE46284 | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
22 Sep, 2029
(4 years from now)
| Active |
| US7799783 | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
16 Dec, 2026
(1 year, 8 months from now)
| Active |
| US6479500 | Agents for alleviating side effects |
16 Mar, 2020
(5 years ago)
| Expired |
| US5744475 | Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same |
28 Mar, 2016
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lonsurf's drug page
3. Lytgobi
Lytgobi is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11833151 | Pharmaceutical composition including sodium alkyl sulfate |
05 Nov, 2039
(14 years from now)
| Active |
| US10434103 | Crystal of 3,5-disubstituted benzene alkynyl compound |
31 Mar, 2036
(11 years from now)
| Active |
| US9108973 | 3,5-disubstituted alkynylbenzene compound and salt thereof |
23 Feb, 2033
(7 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lytgobi's drug page